Christopher Horan Sells 7,002 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Christopher Horan sold 7,002 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total transaction of $63,088.02. Following the transaction, the insider owned 293,450 shares in the company, valued at $2,643,984.50. The trade was a 2.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Price Performance

Shares of Artiva Biotherapeutics stock traded down $0.67 during trading on Tuesday, reaching $8.55. 844,679 shares of the company traded hands, compared to its average volume of 581,930. Artiva Biotherapeutics, Inc. has a 1-year low of $1.47 and a 1-year high of $14.53. The company has a 50 day moving average price of $8.32 and a 200-day moving average price of $5.65. The firm has a market capitalization of $211.36 million, a PE ratio of -2.42 and a beta of 2.86.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Equities research analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Institutional Trading of Artiva Biotherapeutics

Several institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC grew its stake in shares of Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after acquiring an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Artiva Biotherapeutics by 46.8% in the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock worth $498,000 after acquiring an additional 37,053 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Artiva Biotherapeutics in the 4th quarter worth $341,000. Finally, Jane Street Group LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter worth $67,000.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ARTV shares. Needham & Company LLC upped their price objective on shares of Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. HC Wainwright upped their price objective on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Wedbush upped their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Cantor Fitzgerald upped their price objective on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Finally, Wall Street Zen downgraded shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Artiva Biotherapeutics has an average rating of “Moderate Buy” and an average target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.